Skip to main content
  1. Home
  2. Emerging Tech
  3. News

Jet pack crash landing successful, pilot survived

Add as a preferred source on Google

He will likely never forget to wear a helmet again. A Jet Pack International executive in Denver, Colorado crashed during a test flight of a unit he had just modified, according to a report from local television station KDVR. He suffered several significant but non-life threatening injuries, and was released from the hospital the following day.

VP and exhibition pilot Nick Macomber was hovering about 20 feet off the ground when the jet pack malfunctioned and he apparently landed on his knees, according to company CEO Troy Widgery. Macomber had a broken jaw, burns on his arms and legs, an ankle injury, and other injuries requiring 27 stitches. To be clear, he was not wearing any protective headgear.

Recommended Videos

See also: Watch this Australian guy fly his jetpack around the Statue of Liberty

Jet packs can fly up to 80 miles per hour at a maximum altitude of 150 feet for a duration of about 30 seconds. Pilots in demonstration flights and at exhibitions wear helmets, flight suits, and other protective gear.

According to Widgery, the 27-year old Macomber is an experienced Jetpack pilot (who knew such a person existed), with more than 400 flights in exhibitions throughout the U.S., in Ireland and China. He also flew a jet pack off the roof of the Denver Four Seasons Hotel in June 2014. In this case, the crash was apparently a control issue, as the thrust was switched on when he hit the ground.

Jet Pack International is sponsored by Apollo Gum, and the Apollo Jet Pack Team has appearances at sporting events, air shows, music festivals, and even restaurant openings and birthday parties. Wherever they go, it’s a sure bet that from now on, whether in public exhibitions or during test flights, Jet pack pilots will wear full protective gear, or at least helmets.

Federal Aviation Administration investigators were on the scene Friday morning soon after the crash.

Bruce Brown
Bruce Brown Contributing Editor   As a Contributing Editor to the Auto teams at Digital Trends and TheManual.com, Bruce…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more